Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment
OBJECTIVES:
- To determine the feasibility of combination chemotherapy in young adult patients with
acute lymphoid leukemia.
- To determine the complete response rate at the end of induction therapy in these
patients.
- To determine the overall survival of patients treated with these regimens.
- To determine the disease-free survival of patients treated with these regimens.
- To determine the event-free survival of patients treated with these regimens.
- To determine toxicity of these regimens.
- To determine compliance related to dose intensity.
OUTLINE:
- Steroids prephase therapy: All patients receive steroids (i.e., prednisone or
methylprednisolone) and methotrexate.
- Induction therapy (induction Ia followed by Ib): Patients receive induction Ia
comprising vincristine, daunorubicin hydrochloride, asparaginase, and prednisone. They
then receive induction Ib comprising cyclophosphamide, mercaptopurine, and cytarabine.
Patients who achieve hematological remission proceed to consolidation therapy.
- Consolidation therapy: Patients receive consolidation therapy according to risk group.
- Standard-risk patients: Patients receive high-dose methotrexate and
mercaptopurine.
- High-risk patients: Patients receive consolidation therapy in 3 steps.
- Step 1: Patients receive dexamethasone, vincristine, methotrexate,
cytarabine, and asparaginase.
- Step 2: Patients receive dexamethasone, vindesine, methotrexate, ifosfamide,
asparaginase, and daunorubicin hydrochloride.
- Step 3: Patients receive dexamethasone, cytarabine, and asparaginase. After
completion of consolidation therapy, patients proceed to reinduction therapy.
- Reinduction therapy (reinduction IIa followed by IIb): Patients receive reinduction IIa
comprising vincristine, doxorubicin hydrochloride, asparaginase, and dexamethasone.
Patients then receive reinduction IIb comprising cyclophosphamide, thioguanine, and
cytarabine.
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Treatment feasibility
To determinate if the Risk-adapted, MRD-directed therapy improves the estimation of Overall Survival (OS) at 24 months from study entry.
At 24 months from study entry.
No
Roberto Foa, MD
Principal Investigator
Universita Degli Studi "La Sapeinza"
Italy: Ethics Committee
LAL1308
NCT01156883
April 2010
February 2015
Name | Location |
---|